|
HB0036 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: Anti-PD-L1 and anti-TIGIT bifunctional molecule
Lafayette, Indiana1 trial
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Horizon Oncology
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.